|
Jun 29
|
This Psychedelic Drug Flopped on Trial Results. Should You Buy the Dip?
|
|
Jun 27
|
Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial
|
|
Jun 24
|
Compass’ stock slips despite psilocybin trial hitting target
|
|
Jun 23
|
Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial
|
|
Jun 23
|
Compass’ big psychedelic study doesn’t impress investors
|
|
Jun 23
|
Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
|
|
Jun 19
|
Trump Trade: President said to weigh possible U.S. strike against Iran
|
|
Jun 19
|
Psychedelic advocates hopeful Trump administration will support space, STAT says
|
|
Jun 18
|
Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025
|
|
Mar 1
|
COMPASS Pathways plc (CMPS): Among the Best Psychedelic Stocks to Buy in 2025
|
|
Feb 28
|
Psychedelic: GH Research, Compass Pathways report earnings results
|
|
Feb 28
|
Compass Pathways PLC (CMPS) Q4 2024 Earnings Call Highlights: Strategic Financing and R&D ...
|
|
Feb 27
|
Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript
|
|
Feb 27
|
Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights
|
|
Feb 25
|
Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference
|
|
Feb 13
|
It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care
|
|
Aug 28
|
Compass Pathways to participate in three investor conferences in September
|
|
Aug 25
|
Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks
|
|
Aug 1
|
Compass Pathways announces second quarter 2024 financial results and business highlights
|
|
Jul 28
|
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
|